This website uses cookies in order to maximize its functionality and to provide you with better user experience.

Closing this window or continuing to navigate in the website means that you understand and accept the use of cookies in the website. 

Close
Roche Navigation Menu Roche4Med : Roche4Med
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Products
      Products Overview
    • Congresses & Events
      Congresses & Events Overview
    • Comprehensive Genomic Profiling
      Comprehensive Genomic Profiling Overview
    Close

    1 - of results for ""

    No results

    Are you registered? Register now to view Roche scientific information for HCPs!

    • References

      Read more

    • Tecentriq®
    • Mechanism of Action
    • Clinical Data
      • Non-small cell lung cancer
    • Dosing & Administration
    • AR Management
    • Resources
      • Professional Resources
      • Congresses
    • Safety Information
    • References
    • More
      • Mechanism of Action
      • Clinical Data
      • Dosing & Administration
      • AR Management
      • Resources
      • Safety Information
      • References

    You are here:

    1. Products
    2. Tecentriq®
    3. References

    References

    1. TECENTRIQ prescribing information.
    2. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
    3. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
    4. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580-6587.
    5. TECENTRIQ Core Data Sheet. Version 2.0. Roche. [Month of Approval] 2017.
    6. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
    7. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [published online December 12, 2016] [supplementary appendix]. Lancet.doi:10.1016/S0140-6736(16)32517-X.

     

     

     

     


    MatCode Approval No.: -1905-V2-3253

    Share
    Close

    Important notice!

    This website is intended for the use of healthcare professionals only, Please approve that you are a healthcare professional in order to continue using this website.

    Accept Cancel
    • © 2021 Roche Pharmaceuticals (Israel) Ltd.
    • 03.08.2020
    • Legal Information

    • Find us on YouTube